696 related articles for article (PubMed ID: 26049964)
41. Demystifying biosimilars: development, regulation and clinical use.
Rugo HS; Rifkin RM; Declerck P; Bair AH; Morgan G
Future Oncol; 2019 Mar; 15(7):777-790. PubMed ID: 30500264
[TBL] [Abstract][Full Text] [Related]
42. The use of biosimilar drugs in psoriasis: a position paper.
Carretero Hernández G; Puig L;
Actas Dermosifiliogr; 2015 May; 106(4):249-51. PubMed ID: 25712906
[No Abstract] [Full Text] [Related]
43. Biosimilars for the management of rheumatoid arthritis: economic considerations.
Gulácsi L; Brodszky V; Baji P; Kim H; Kim SY; Cho YY; Péntek M
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S43-52. PubMed ID: 26395836
[TBL] [Abstract][Full Text] [Related]
44. A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.
Ha CY; Kornbluth A
Inflamm Bowel Dis; 2016 Oct; 22(10):2513-26. PubMed ID: 27564646
[TBL] [Abstract][Full Text] [Related]
45. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.
Jha A; Upton A; Dunlop WC; Akehurst R
Adv Ther; 2015 Aug; 32(8):742-56. PubMed ID: 26343027
[TBL] [Abstract][Full Text] [Related]
46. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice.
Cohen AD; Wu JJ; Puig L; Chimenti S; Vender R; Rajagopalan M; Romiti R; de la Cruz C; Skov L; Zachariae C; Young HS; Foley P; van der Walt JM; Naldi L; Prens EP; Blauvelt A
Br J Dermatol; 2017 Dec; 177(6):1495-1502. PubMed ID: 28646580
[TBL] [Abstract][Full Text] [Related]
47. Biosimilar infliximab: an expert view.
Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
[TBL] [Abstract][Full Text] [Related]
48. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience.
Barker J; Girolomoni G; Egeberg A; Goncalves J; Pieper B; Kang T
J Dermatolog Treat; 2020 Dec; 31(8):794-800. PubMed ID: 31094242
[TBL] [Abstract][Full Text] [Related]
49. Bioequivalence studies with anti-TNF biosimilars.
Gimeno-Gracia M; Gargallo-Puyuelo CJ; Gomollón F
Expert Opin Biol Ther; 2019 Oct; 19(10):1031-1043. PubMed ID: 30574813
[No Abstract] [Full Text] [Related]
50. Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database.
Pauline O; Robert M; Bernardeau C; Hlavaty A; Fusaroli M; Roustit M; Cracowski JL; Khouri C
BioDrugs; 2023 Sep; 37(5):699-707. PubMed ID: 37278971
[TBL] [Abstract][Full Text] [Related]
51. Pharmacovigilance and biosimilars: considerations, needs and challenges.
Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
[TBL] [Abstract][Full Text] [Related]
52. Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRAS main and extension studies: utility of laboratory methods description.
Meacci F; Manfredi M; Infantino M; Grossi V; Benucci M
Ann Rheum Dis; 2016 Oct; 75(10):e62. PubMed ID: 27401744
[No Abstract] [Full Text] [Related]
53. Biosimilars for the treatment of psoriasis.
Puig L; López-Ferrer A
Expert Opin Biol Ther; 2019 Oct; 19(10):993-1000. PubMed ID: 31237786
[No Abstract] [Full Text] [Related]
54. Biosimilar regulation in the EU.
Kurki P; Ekman N
Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
[TBL] [Abstract][Full Text] [Related]
55. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.
Farkas K; Molnár T
Immunotherapy; 2018 Feb; 10(2):107-117. PubMed ID: 29124994
[TBL] [Abstract][Full Text] [Related]
56. Biosimilars in psoriasis: the future or not?
Kellen R; Goldenberg G
Cutis; 2017 Feb; 99(2):116-120. PubMed ID: 28319617
[TBL] [Abstract][Full Text] [Related]
57. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.
Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E
Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876
[TBL] [Abstract][Full Text] [Related]
58. The Regulation of Biosimilars in Latin America.
Garcia R; Araujo DV
Curr Rheumatol Rep; 2016 Mar; 18(3):16. PubMed ID: 26951254
[TBL] [Abstract][Full Text] [Related]
59. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
60. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
